Last reviewed · How we verify
Hutchinson-Gilford syndrome — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Zokinvy | LONAFARNIB | Sentynl Theraps Inc | Farnesyltransferase Inhibitor [EPC] | farnesyltransferase | 2020-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Sentynl Theraps Inc · 1 drug in Hutchinson-Gilford syndrome
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Hutchinson-Gilford syndrome:
- Hutchinson-Gilford syndrome treatment updates — RSS
- Hutchinson-Gilford syndrome treatment updates — Atom
- Hutchinson-Gilford syndrome treatment updates — JSON
Cite this brief
Drug Landscape (2026). Hutchinson-Gilford syndrome — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/hutchinson-gilford-syndrome. Accessed 2026-06-10.
Related
- Hutchinson-Gilford syndrome full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing